GLP-2

GLP-2 (glucagon-like peptide-2) is a 33-amino-acid proglucagon-derived peptide supplied in lyophilized form for laboratory research and professional reference use. It is structurally distinct from the better-known GLP-1 incretin and is studied primarily in the context of intestinal and gastrointestinal physiology rather than systemic glucose handling. This material is offered solely as a research compound for licensed practitioners and qualified investigators; it is not approved by the FDA for therapeutic use and is not intended to diagnose, treat, cure, or prevent any condition. Within the Weight Loss & Metabolic catalog grouping, it is of research interest to those examining gut-nutrient signaling, intestinal mucosal biology, and the broader proglucagon peptide family. Any references to observed effects derive from published preclinical and exploratory literature, and individual results vary.

• Investigated in preclinical literature for its reported role in intestinal mucosal growth and epithelial cell proliferation
• Studied in research models exploring gut barrier integrity and intestinal permeability
• Examined in animal studies for its reported association with nutrient absorption and gastrointestinal adaptation following intestinal stress or resection
• Reported in research contexts exploring proglucagon-derived peptide signaling within the enteroendocrine system
• Investigated as a comparator in studies characterizing the broader GLP peptide family and the gut-brain-metabolic axis

For research handling reference only: the lyophilized peptide is typically reconstituted with bacteriostatic water (or another suitable sterile diluent selected by the investigator) added slowly against the vial wall, then gently swirled rather than shaken until fully dissolved. Unreconstituted vials are generally stored frozen and protected from light and moisture; once reconstituted, material is commonly kept refrigerated, protected from light, and used within a limited window consistent with standard peptide-stability practices. Repeated freeze-thaw cycles and excessive agitation should be avoided, as these may degrade peptide integrity. All clinical and dosing protocols are determined solely by the licensed ordering provider at their professional discretion; this is reference information for research and professional use only and does not constitute medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, GLP-2 is described as acting through a specific G-protein-coupled receptor (the GLP-2 receptor) that is reported to be expressed predominantly within intestinal and related tissues. Studies propose that receptor engagement is associated with downstream signaling linked to enterocyte proliferation, reduced epithelial apoptosis, and modulation of intestinal blood flow and barrier function. It is reported to be secreted alongside GLP-1 from enteroendocrine L-cells in response to nutrient intake, and researchers have investigated its proposed paracrine and trophic signaling within the gut rather than a primary insulinotropic role. These mechanistic descriptions reflect preclinical and exploratory findings; effects are not established for clinical use and individual results vary.